Back to EUR-Lex homepage

EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search
You are here

Document 32024R2102

Commission Implementing Regulation (EU) 2024/2102 of 30 July 2024 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use of the novel food 2'-Fucosyllactose and as regards the specifications of the novel food 2'-Fucosyllactose produced with a derivative strain of Escherichia coli BL-21

C/2024/5399

OJ L, 2024/2102, 31.7.2024, ELI: http://data.europa.eu/eli/reg_impl/2024/2102/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

Legal status of the document Date of entry into force unknown (pending notification) or not yet in force., Date of effect: 20/08/2024

ELI: http://data.europa.eu/eli/reg_impl/2024/2102/oj

Date of document:
30/07/2024; Date of adoption
Date of effect:
20/08/2024; Entry into force Date pub. +20 See Art 2
Date of end of validity:
No end date
Author:
European Commission, Directorate-General for Health and Food Safety
Responsible body:
SANTE
Form:
Implementing regulation
Additional information:
EEA relevance
Treaty:
Treaty on the Functioning of the European Union
Legal basis:
Link
Link
Link
Select all documents mentioning this document
Modifies:
Relation Act Comment Subdivision concerned From To
Modifies 32017R2470 Replacement annex table 1 Text 20/08/2024
Modifies 32017R2470 Replacement annex table 2 Text 20/08/2024
Instruments cited:
European flag

Official Journal
of the European Union

EN

L series

2024/2102

31.7.2024

COMMISSION IMPLEMENTING REGULATION (EU) 2024/2102

of 30 July 2024

amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use of the novel food 2'-Fucosyllactose and as regards the specifications of the novel food 2'-Fucosyllactose produced with a derivative strain of Escherichia coli BL-21

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 (1), and in particular Article 12 thereof,

Whereas:

(1)

Regulation (EU) 2015/2283 provides that only novel foods authorised and included in the Union list of novel foods may be placed on the market within the Union.

(2)

Pursuant to Article 8 of Regulation (EU) 2015/2283, Commission Implementing Regulation (EU) 2017/2470 (2) has established a Union list of authorised novel foods.

(3)

The Union list set out in the Annex to Implementing Regulation (EU) 2017/2470 includes both chemically synthesised and microbiologically produced 2'-Fucosyllactose (‘2′-FL’) as an authorised novel food. The conditions of use, maximum levels and specific labelling requirements set out in Table 1 of the Annex to that Regulation are common for both the synthetically and the microbiologically produced 2′-FL. At the same time, in in Table 2 of the Annex of that Regulation, separate specifications are set out for chemically synthesised 2′-FL (‘2'-Fucosyllactose (synthetic)’) and for microbiologically produced 2′-FL (‘2'-Fucosyllactose (microbial source)’).

(4)

On 30 June 2021, the company Chr. Hansen A/S (‘the applicant’) submitted an application to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 for a change in the conditions of use of 2'-FL. The applicant requested to increase in the maximum authorised levels of 2'-FL in infant formulae and follow-on formulae as defined in Article 2 of Regulation (EU) No 609/2013 of the European Parliament and of the Council (3), from the currently authorised 1,2 g/L in both infant formulae and follow-on formulae to 3,0 g/L in infant formulae and to 3,64 g/L in follow-on formulae.

(5)

In accordance with Article 10(3) of Regulation (EU) 2015/2283, the Commission consulted the European Food Safety Authority (‘the Authority’) on 28 September 2022 requesting it to provide a scientific opinion on the proposed increase in the maximum authorised levels of 2'-FL in infant formulae and follow-on formulae.

(6)

On 26 September 2023, the Authority adopted its scientific opinion on the ‘Safety of the extension of use of 2′-fucosyllactose (2′-FL) as a novel food pursuant to Regulation (EU) 2015/2283’ (4), in accordance with Article 11 of Regulation (EU) 2015/2283.

(7)

In its scientific opinion, the Authority concluded that 2′-FL is safe when used in infant formulae and follow-on formulae at the proposed maximum levels of 3,0 g/L and 3,64 g/L respectively, and therefore it is appropriate to amend the conditions of use of 2′-FL.

(8)

The information provided in the application and the Authority’s scientific opinion give sufficient grounds to establish that the changes to the conditions of use of 2′-FL are in accordance with Article 12(1) of Regulation (EU) 2015/2283.

(9)

On 27 October 2023, the applicant submitted another application to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 for a change in the specifications of 2'-FL produced by fermentation using a derivative strain of Escherichia coli BL-21. The applicant requested the increase in the authorised maximum levels of residual endotoxins from the currently authorised ≤ 100 Endotoxin Units (‘EU’)/g (or ≤ 0,1 EU/mg) of novel food for the powder form or ≤ 100 EU/ml (or ≤ 0,1 EU/μl) of novel food for the liquid form to ≤ 10 EU/mg of novel food for the powder form or ≤ 10 EU/μl of novel food for the liquid form.

(10)

The applicant requested to increase the residual endotoxins for 2'-FL produced by fermentation using a derivative strain of Escherichia coli BL-21 to align them to those of the already authorised 2'-FL produced with a derivative strain of Escherichia coli K-12, which is authorised under the same conditions of use, and that of other authorised human identical milk oligosaccharides which are also authorised at identical or similar residual endotoxin levels in infant formulae and follow-on formulae.

(11)

The Commission considers that the requested update of the Union list of novel foods to increase the residual endotoxins in the specifications of 2'-FL produced with a derivative strain of Escherichia coli BL-21 is not liable to have an effect on human health, and that a safety evaluation by the Authority in accordance with Article 10(3) of Regulation (EU) 2015/2283 is not necessary. The Authority’s opinions (5) , (6) , (7) on other currently authorised human identical milk oligosaccharides with residual endotoxin levels ≤ 10 EU/mg of novel food and with the same or similar conditions of use as 2'-FL produced with a derivative strain of Escherichia coli BL-21, concluded that these maximum levels of residual endotoxins, are safe.

(12)

The information provided in the applications and the Authority’s existing opinions give sufficient grounds to establish that the changes in the conditions of use of 2'-FL to increase its maximum use levels in infant formulae and follow-on formulae and the changes in the specifications of 2'-FL produced by fermentation using a derivative strain of Escherichia coli BL-21 to modify the levels of residual endotoxins, are in accordance with the conditions of Article 12 of Regulation (EU) 2015/2283 and should be approved.

(13)

The Annex to Implementing Regulation (EU) 2017/2470 should therefore be amended accordingly.

(14)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

The Annex to Implementing Regulation (EU) 2017/2470 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 30 July 2024.

For the Commission

The President

Ursula VON DER LEYEN

(1)   OJ L 327, 11.12.2015, p. 1. ELI: http://data.europa.eu/eli/reg/2015/2283/oj.

(2)  Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (OJ L 351, 30.12.2017, p. 72, ELI: http://data.europa.eu/eli/reg_impl/2017/2470/oj).

(3)  Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009 (OJ L 181, 29.6.2013, p. 35, ELI: http://data.europa.eu/eli/reg/2013/609/oj.

(4)   EFSA Journal 2023;21(11):8334.

(5)   EFSA Journal 2019;17(6):5717.

(6)   EFSA Journal 2022;20(5):7329.

(7)   EFSA Journal 2023;21(6):8026.

ANNEX

The Annex to Implementing Regulation (EU) 2017/2470 is amended as follows:

(1)

in Table 1 (Authorised novel foods), the entry for 2'-Fucosyllactose is replaced by the following:

Authorised novel food

Conditions under which the novel food may be used

Additional specific labelling requirements

Other requirements

‘2′-Fucosyllactose

Specified food category

Maximum levels

1.

The designation of the novel food on the labelling of the foodstuffs containing it shall be “2′-Fucosyllactose”.

2.

The labelling of food supplements containing 2′-Fucosyllactose shall bear a statement that the supplements should not be used if other foods with added 2′-fucosyllactose are consumed the same day.

3.

The labelling of food supplements containing 2′-Fucosyllactose intended for young children shall bear a statement that the supplements should not be used if breast milk or other foods with added 2′-fucosyllactose are consumed the same day.’

 

Unflavoured pasteurised and sterilised (including UHT) milk-based products

1,2 g/l

Unflavoured fermented milk-based products

1,2 g/l for beverages

19,2 g/kg for products other than beverages

Flavoured fermented milk-based products including heat-treated products

1,2 g/l for beverages

19,2 g/kg for products other than beverages

Dairy analogues, including beverage whiteners

1,2 g/l for beverages

12 g/kg for products other than beverages

400 g/kg for whitener

Cereal bars

12 g/kg

Table-top sweeteners

200 g/kg

Infant formula as defined in Regulation (EU) No 609/2013

3,0 g/l in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer

Follow-on formula as defined in Regulation (EU) No 609/2013

3,64 g/l in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer

Processed cereal-based foods and baby foods for infants and young children as defined in Regulation (EU) No 609/2013

12 g/kg for products other than beverages

1,2 g/l for liquid food ready for use, marketed as such or reconstituted as instructed by the manufacturer

Milk based drinks and similar products intended for young children

1,2 g/l for milk-based drinks and similar products in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer

Foods for special medical purposes as defined in Regulation (EU) No 609/2013

In accordance with the particular nutritional requirements of the persons for whom the products are intended

Total diet replacement for weight control as defined in Regulation (EU) No 609/2013

4,8 g/l for drinks

40 g/kg for bars

Bread and pasta products bearing statements on the absence or reduced presence of gluten in accordance with the requirements of Implementing Regulation (EU) No 828/2014

60 g/kg

Flavoured drinks

1,2 g/l

Coffee, tea (excluding black tea), herbal and fruit infusions, chicory; tea, herbal and fruit infusions and chicory extracts; tea, plant, fruit and cereal preparations for infusions, as well as mixes and instant mixes of these products

9,6 g/l – the maximum level refers to the products ready to use

Food supplements as defined in Directive 2002/46/EC, for the general population, excluding infants

3,0 g/day for general population

1,2 g/day for young children

(2)

in Table 2 (Specifications) the entry for 2′-Fucosyllactose (microbial source) is replaced by the following:

Specifications

 

Data protection

 

Definition:

Chemical name: α-L-Fucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→4)-D-glucopyranose

Chemical formula: C18H32O15

CAS No: 41263-94-9

Molecular weight: 488,44 g/mol

2′-Fucosyllactose produced with a genetically modified strain of Corynebacterium glutamicum ATCC 13032 authorised on 16 May 2023. This inclusion is based on proprietary scientific evidence and scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283.

Applicant: “Advanced Protein Technologies Corporation”, 7th Floor GyeongGi-BioCenter, 147, Gwanggyo-ro, Yeongtong-gu, Suwon-si Gyeonggi-do, 16229 South Korea. During the period of data protection, 2′-Fucosyllactose produced with a genetically modified strain of Corynebacterium glutamicum ATCC 13032 is authorised for placing on the market within the Union only by “Advanced Protein Technologies Corporation” unless a subsequent applicant obtains authorisation for the novel food without reference to the proprietary scientific evidence or scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283 or with the agreement of “Advanced Protein Technologies Corporation”.

End date of the data protection: 16 May 2028.’

‘2′-Fucosyllactose

(microbial source)

Source: Genetically modified strain of Escherichia coli K-12

Source: Genetically modified strain of Escherichia coli BL-21

Source: Genetically modified strain of Corynebacterium glutamicum ATCC 13032

Description:

2′-Fucosyllactose is a white to off-white powder that is produced by a microbiological process.

Purity:

2′-Fucosyllactose: ≥ 83 %

D-Lactose: ≤ 10,0 %

L-Fucose: ≤ 2,0 %

Difucosyl-D-lactose: ≤ 5,0 %

2′-Fucosyl-D-lactulose: ≤ 1,5 %

Sum of saccharides (2′-Fucosyllactose, D-Lactose, L-Fucose, Difucosyl-D-lactose, 2′-Fucosyl-D-lactulose): ≥ 90 %

pH (20 C, 5 % solution): 3,0-7,5

Water: ≤ 9,0 %

Sulphated ash: ≤ 2,0 %

Acetic acid: ≤ 1,0 %

Residual proteins: ≤ 0,01 %

Microbiological criteria:

Aerobic mesophilic bacteria total count: ≤ 3 000 CFU/g

Yeasts: ≤ 100 CFU/g

Moulds: ≤ 100 CFU/g

Endotoxins: ≤ 10 EU/mg

CFU: Colony Forming Units; EU: Endotoxin Units

Description:

2′-Fucosyllactose is a white to off white powder and the liquid concentrate (45 % ± 5 % w/v) aqueous solution is a colourless to slight yellow clear aqueous solution. 2′-Fucosyllactose is produced by a microbiological process.

Purity:

2′-Fucosyllactose: ≥ 90 %

Lactose: ≤ 5,0 %

Fucose: ≤ 3,0 %

3-Fucosyllactose: ≤ 5,0 %

Fucosylgalactose: ≤ 3,0 %

Difucosyllactose: ≤ 5,0 %

Glucose: ≤ 3,0 %

Galactose: ≤ 3,0 %

Water: ≤ 9,0 % (powder)

Ash, sulphated: ≤ 0,5 % (powder and liquid)

Residual proteins: ≤ 0,01 % (powder and liquid)

Heavy Metals:

Lead: ≤ 0,02 mg/kg (powder and liquid)

Arsenic: ≤ 0,2 mg/kg (powder and liquid)

Cadmium: ≤ 0,1 mg/kg (powder and liquid)

Mercury: ≤ 0,5 mg/kg (powder and liquid)

Microbiological criteria:

Total plate count: ≤ 104 CFU/g (powder), ≤ 5 000 CFU/g (liquid)

Yeasts and Moulds: ≤ 100 CFU/g (powder); ≤ 50 CFU/g (liquid)

Enterobacteriaceae/Coliforms: absence in 11 g (powder and liquid)

Salmonella: negative/100 g (powder), negative/200 ml (liquid)

Cronobacter: negative/100 g (powder), negative/200 ml (liquid)

Endotoxins: ≤ 10 EU/mg (powder), ≤ 10 EU/μl (liquid)

Aflatoxin M1: ≤ 0,025 μg/kg (powder and liquid)

CFU: Colony Forming Units; EU: Endotoxin Units

Description:

2′-Fucosyllactose is a white to off white/ivory powder that is produced by a microbiological process.

Purity:

2′-Fucosyllactose (w/w dry matter): ≥ 94,0 %

D-Lactose (w/w dry matter): ≤ 3,0 %

L-Fucose (w/w dry matter): ≤ 3,0 %

3-Fucosyllactose (w/w dry matter): ≤ 3,0 %

Difucosyllactose (w/w dry matter): ≤ 2,0 %

D-Glucose (w/w dry matter): ≤ 3,0 %

D-Galactose (w/w dry matter): ≤ 3,0 %

Water: ≤ 9,0 %

Ash: ≤ 0,5 %

Residual proteins: ≤ 0,005 %

Contaminants:

Arsenic: ≤ 0,03 mg/kg

Aflatoxin M1: ≤ 0,025 μg/kg

Ethanol: ≤ 1 000 mg/kg

Microbiological criteria:

Total plate count: ≤ 500 CFU/g

Yeasts and Moulds: ≤ 100 CFU/g

Enterobacteriaceae: absence in 10 g

Salmonella: absence in 25 g

Cronobacter spp.: absence in 10 g

Endotoxins: ≤ 100 EU/g

CFU: Colony Forming Units; EU: Endotoxin Units

 

 

 

 

ELI: http://data.europa.eu/eli/reg_impl/2024/2102/oj

ISSN 1977-0677 (electronic edition)

Top